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Chronic nasal carriage of the bacterium Staphylococcus aureus in patients with the autoimmune disease
granulomatosis with polyangiitis (GPA) is a risk factor for disease relapse. To date, it was neither known
whether GPApatients show similar humoral immune responses to S. aureus as healthy carriers, nor whether
specific S. aureus types are associated with GPA. Therefore, this study was aimed at assessing humoral
immune responses of GPA patients against S. aureus antigens in relation to the genetic diversity of their
nasal S. aureus isolates. A retrospective cohort study was conducted, including 85 GPA patients and 18
healthy controls (HC). Humoral immune responses against S. aureus were investigated by determining
serum IgG levels against 59 S. aureus antigens. Unexpectedly, patient sera contained lower
anti-staphylococcal IgG levels than sera fromHC, regardless of the patients’ treatment, while total IgG levels
were similar or higher. Furthermore, 210 S. aureus isolates obtained from GPA patients were characterized
by different typing approaches. This showed that the S. aureus population of GPA patients is highly diverse
and mirrors the general S. aureus population. Our combined findings imply that GPA patients are less
capable of mounting a potentially protective antibody response to S. aureus than healthy individuals.
G
ranulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by small-vessel
vasculitis and chronic necrotizing granulomatous inflammation with a predilection for the upper and
lower respiratory tract and kidneys1. GPA is further characterized by the presence of anti-neutrophil
cytoplasmic antibodies (ANCA) against proteinase 3 (PR3). Although the etiopathogenesis of GPA has been
studied extensively and various genetic and environmental factors are known to contribute to inflammation, the
primary cause of this disease is still debated2–5. However, upper airways infections have been repeatedly linked to
GPA2,3,6–9.
Approximately 60–70% of GPA patients are chronic nasal carriers of the opportunistic pathogen
Staphylococcus aureus, and nasal S. aureus carriage is associated with an increased risk of relapse6,8,10.
Consistent with these findings, anti-bacterial treatment with co-trimoxazole reduces the risk of relapse11,12. To
date, the precise mechanism by which S. aureus could exert a pathophysiological role in GPA has remained
enigmatic. In view of the persistent activation of circulating T cells, staphylococcal superantigens (SAgs) were
invoked as chronic stimuli of aberrant immune responses13. Indeed, it was shown that GPA patients carrying S.
aureus positive for the superantigen toxic shock syndrome toxin-1 (TSST-1) have an increased risk for relapse,
although earlier studies had not revealed a correlation between the presence of SAg genes and the expansion of
specific T cell subsets in peripheral blood14,15.
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S. aureus carriage, occurring in 20–30% of the general human
population, is usually asymptomatic. However this bacterium can
cause serious infections16. Epidemiological studies have shown that
certain clonal lineages of S. aureus attain a geo-spatial predominance,
but clear associations of specific S. aureus types with specific diseases
have not been reported17–19. Nevertheless, it is known that virulence
factors, like TSST-1 and exfoliative toxins, cause particular disease
phenotypes, such as toxic shock syndrome and staphylococcal
scalded skin syndrome, respectively20–22.
Information on anti-staphylococcal immune responses in GPA
patients and in-depth genetic analyses of their S. aureus isolates have
so far been lacking. Hence, it was unknown towhich extent particular
S. aureus antigens or types may contribute to GPA. To address these
questions, we performed a retrospective study in 85 GPA patients.
We first investigated the humoral immune response against S. aureus
by determining serum antibody levels against a comprehensive set of
S. aureus antigens. Subsequently, the S. aureus isolates were genetic-
ally characterized to investigate whether specific S. aureus types col-
onize GPA patients.
Results
Low levels of anti-staphylococcal antibodies in GPA patients.
Serum IgG levels against 59 S. aureus antigens were measured in
35 GPA patients (21 carriers, 14 non-carriers) and 18 healthy
control (HC) individuals (10 carriers, 8 non-carriers) by bead-
based Luminex flow cytometry. The overall antibody responses
showed broad variability in both groups (Figure 1A). The highest
median antibody titers were observed against several secreted
proteins. In GPA patients, the IgG responses per antigen appeared
overall lower than in HC, and this reached statistical significance for
several surface proteins (ClfA, ClfB, FnbpA, and SdrE) and secreted
proteins (Atl-2, CHIPS, Efb, Lipase, NUC, SCIN, SEN, SEO, SSL3
and TSST-1). For HC, multiple sera from different time points were
measured, but serum IgG levels against S. aureus proteins did not
Figure 1 | IgG responses of GPA patients and HC to staphylococcal antigens. Serum IgG levels against 59 S. aureus antigens were determined by bead-
based Luminex flow cytometry in GPA patients, 21 S. aureus carriers (55 sera) and 14 non-carriers (29 sera), and HC, 10 S. aureus carriers (22 sera)
and 8 non-carriers (20 sera). The S. aureus antigens comprised 10 surface proteins, 26 secreted proteins, 21 superantigens and superantigen-like proteins
and 2 proteins of unknown function (indicated as others). (A) Serum IgG responses of all GPA patients (in blue) andHC (in red) to 59 S. aureus antigens.
Depicted are themedian with boxes (25% and 75%) andwhiskers (10% and 90%) of all sera per group. (B) Serum IgG responses to S. aureus antigens that
were different between S. aureus-carrying and non-carrying GPA patients or HC. For every indicated antigen higher responses were found in S. aureus
carriers than non-carriers. Depicted are the individual responses andmedian. (C) Serum IgG responses to S. aureus antigens that were different between S.
aureus-carrying GPA patients and S. aureus-carrying HC. Depicted are the individual responses and median. Statistical significances in A were tested
using Mann Whitney-U test and in B and C using the Kruskal-Wallis test (with post-hoc Dunn’s test). * p , 0.05, **p , 0.01, *** p , 0.001, and
**** p , 0.0001.
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change in time (data not shown). For GPA patients, two to three sera
were included from the time of diagnosis, remission and/or relapse,
but no differences were observed between the different disease states
(data not shown). Despite the broad inter-individual variability,
some clear differences were observed between S. aureus carriers
and non-carriers in both patients and HC. As expected, overall
higher responses were found in S. aureus carriers than non-carriers
(Figure 1B). Amongst the S. aureus carriers, serum IgG levels against
the surface proteins ClfA, ClfB and SdrE, and the secreted proteins
EfB, Nuc, Pro-Atl, SEN, SEO, SSL3 and TSST-1, were lower in
patients than in HC (Figure 1C) irrespective of the immuno-
suppressive and/or corticosteroid treatment of the patients (data
not shown). Furthermore, we also measured total IgG in a subset
of sera from patients and HC. This showed that the patient sera
contained equal or even higher total IgG levels than HC (Table 1).
Altogether, these findings show that GPA patients have lower levels
of IgGs against many staphylococcal antigens than HC, irrespective
of the patients’ treatment.
Detection of antigen-encoding genes in S. aureus isolates from
GPA patients. To determine whether there is a direct connection
between IgG responses to particular S. aureus antigens and the
bacterial production of these antigens, we assessed the presence of
the corresponding genes in S. aureus isolates from 21 of the
investigated patients (75 isolates) and 10 HC (18 isolates)
(Supplementary Table 5) by DNA microarray-based genotyping.
The genes for the surface proteins ClfA, ClB, FnbpA and the
secreted nuclease were present in all isolates from patients and HC.
Interestingly, the genes for the superantigens TSST-1, SEN and SEO
were less frequently detected in patient than HC isolates (5% vs 44%,
24% vs 72%, and 24% vs 72%, respectively) corresponding to the
lower IgG levels against these antigens in patients, while the gene
for the superantigen SEB was only detected in patient isolates (33%)
corresponding to the higher IgG levels against SEB in patients.
Otherwise, the S. aureus isolates from patients and HC had,
overall, a comparable gene repertoire. Therefore, the decreased IgG
responses against particular proteins (e.g. ClfA, ClfB, FnbpA) in
GPA patients cannot be attributed to a lower abundance of the
corresponding genes in their S. aureus isolates.
The S. aureus population in GPA patients mirrors the general S.
aureus population structure. The genetic diversity of the colonizing
S. aureus isolates was determined using two complementary typing
methods, namely spa-typing and multiple-locus variable number
tandem repeat fingerprinting (MLVF)23. For this purpose, the S.
aureus collection was extended to 210 isolates from 71 GPA
patients. The single-locus spa-typing approach yielded 55 different
spa-types, ranging in length between 3 (t026) and 14 (t328) repeats.
Additionally, five novel spa-types were identified, and two isolates
(Vas103 and Vas106) were not spa-typable. Thirty-one spa-types
were represented by $2 isolates (184 isolates in total), while 24
spa-types were represented by single isolates. The most frequent
spa-types were t064 (n 5 46, 21 patients), t084 (n 5 26, 16
patients), t091 (n 5 19, 8 patients), t012 (n 5 10, 7 patients) and
t021 (n 5 10, 7 patients), covering 52.4% of the investigated patient
isolates. Intriguingly, the prevalence of four predominant spa-types
showed a shift over time; t084 and t012 were solely found between
1990–2003, while t064 and t091 were predominantly found since
2000 (Figure 2A). Of the 58 patients who provided .1 S. aureus
isolate, 39 carried isolates with different spa-types over time,
whereas isolates from the 19 other patients showed the same spa-
type over time. Analysis of the S. aureus population structure in GPA
patients with the BURP algorithm revealed the respective spa clonal
complexes (spa-CCs; Figure 2B)24. The 18 HC isolates yielded 12
different spa-types that partly overlapped with the spa-types of
patient isolates (Supplementary Table 3).
Typing of the 210 patients’ isolates by MLVF identified 95 differ-
ent MLVF banding patterns. Fifty-one patterns were represented by
one isolate, whereas 44 patterns were represented by $2 isolates.
Notably, two MLVF patterns were represented by 18 and 27 isolates,
respectively. The highest concordance (Adjusted Rand’s Coefficient
0.671) between MLVF and spa-typing was found with a 66% sim-
ilarity cut-off value, resulting in 30 clusters (Figure 3). Six clusters
contained single isolates whereas 24 clusters contained $2 isolates.
Four clusters contained$12 isolates (61 isolates [C17], 32 [C26], 18
[C16] and 12 [C3]) and were derived from 27, 21, 7, and 8 patients
respectively. Of the 58 patients who provided.1 isolate, 33 carried S.
aureus belonging to different MLVF clusters over time, whereas the
remaining 25 patients carried S. aureus belonging to the sameMLVF
cluster. The isolates from18 of the latter 25 patients also had the same
spa-type. Altogether, the combined typing data suggest that the S.
aureus population structure in GPA patients is highly diverse, and
that it has changed over time.
Table 1 | Clinical data of GPA patients and HC whose serum samples were included in the multiplex S. aureus antibody assay
Group
S. aureus
carriership
No. of
subjects
No. of
sera
No. of male/
female
Age (years) mean 6
SD
No. receiving
vasculitis
treatmenta/
antibioticsb
BVAS Median
(range)
Total IgG (g/
L)c
mean 6 SD
GPA Carrier 21 11/10 51.6 6 16.3
Diagnosis 14 0/2 14 (4–32) 15.8 6 5.9$
Remissiond 21 13/16 0 (0–2) 11.0 6 2.4
Relapsee 20 9/14 6 (3–16) 10.5 6 2.9
GPA Non-carrier 14 9/5 54.3 6 17.4
Diagnosis 13 4f/4 21 (8–28) 10.7 6 2.1
Remissionc 12 9/8 0 (0–0) 8.5 6 2.1
Relapsed 4 2/2 14.5 (11–19) 10.1 6 1.0
HC Carrier 10 22 4/6 33.6 6 11.8* None n.a. 11.3 6 1.2
HC Non-carrier 8 20 1/7 40.1 6 12.2 None n.a. 11.6 6 1.2
aVasculitis treatment consisted of azathioprine, (methyl) prednisolone, methotrexate, cyclophosphamide or mycophenolate mofetil.
bAntibiotic treatment consisted of maintenance treatment with co-trimoxazole (ranging between 0.5–3 3 960 mg daily, oral intake), in one case a patient received flucloxacilline (3 3 250 mg daily, oral
intake) and in one case a patient received augmentin (2 3 1200 mg daily, oral intake).
cLevels of total IgG were routinely measured on a BNII nephelometer (Siemens Healthcare) in respectively 12, 10, 9, 6, 10, 3, 13 and 7 sera of the different groups.
dRemission serum samples were taken from GPA patients in stable remission with minimal immunosuppression, defined as: no active disease for $12 months, no cyclophosphamide for $3 months,
azathioprine (or methothrexate or mycophenolate mophetil) as maintenance therapy (#100 mg/day) in combination with prednisolone #10 mg/day allowed, and co-trimoxazole allowed.
eRelapse serum samples were taken from GPA patients irrespective of their treatment. fVasculitis treatment of these patients consisting of (methyl) prednisolone in combination with cyclophosphamide had
started respectively 2, 7, 10 and 14 days before the serum sample was taken. Abbreviations: BVAS 5 Birmingham Vasculitis Activity Score; n.a. 5 not applicable.
*p , 0.05 vs GPA carrier and GPA non-carrier with one-way ANOVA followed by Tukey’s post-test.
$p , 0.05 vs GPA carriers remission and relapse, GPA non-carriers diagnosis and remission, and HC carriers with one-way ANOVA followed by Tukey’s post-test.
www.nature.com/scientificreports
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Figure 2 | Spa-types of the 210 S. aureus isolates fromGPA patients presented as (A) the five most frequent identified spa-types displayed by year and
number and (B) spa clonal complexes. (A) The frequencies of the 5 predominant spa-types, i.e. t012 (dark blue), t084 (light blue), t064 (red), t091
(orange), t021 (white), and all other spa-types (black) found amongst the 210 S. aureus isolates from GPA patients are shown throughout the whole
collection period (1990–2012). (B) The clustering of the 210 S. aureus isolates fromGPApatients into clonal lineages was performed by BURP analysis. spa
clonal complexes (spa-CCs) were composed of $2 related spa-types. A spa-type not clustered into any spa-CC was regarded as non-clonal (singleton).
spa-types defined as founders of particular clusters are indicated in blue. The circle size is proportional to the number of isolates. The intensity of
connecting lines indicates the evolutionary relationship. One hundred and forty nine isolates (71% of all isolates) were clustered in 5 spa-CCs (CC064,
CC084, CC012, CC330/180 and CC062) and 4 groups without founder. Fifty isolates (24% of all isolates) comprising 17 spa-types (30% of all spa-types)
were identified as singletons. Nine isolates (4%of all isolates) comprising two spa-types (t026 and t842, 4%of all spa-types) were excluded and two isolates
(Vas103 and Vas106, 1% of all isolates) were not spa-typable.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8188 | DOI: 10.1038/srep08188 4
Figure 3 | MLVF dendrogram of the 210 S. aureus isolates from GPA patients. An MLVF dendrogram of the 210 S. aureus isolates from GPA patients
was generated by the UPGMA algorithm. Isolate clusters were delineated with a 66% similarity cut-off value, since this showed the highest
concordance between MLVF and spa-typing (Adjusted Rand’s Coefficient 0.671). Additionally to the 210 studied S. aureus isolates from GPA patients,
also 22 control samples of the control isolateM2were included in this delineation. The names of clusters are indicated at the right side of the dendrogram.
www.nature.com/scientificreports
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Relationship between the shift in spa-CCs over time and antibiotic
resistance profiles.The resistances to 18 different antibiotics and the
antibiotic resistance genotypes of all 210 S. aureus isolates fromGPA
patients are shown in Table 3.While these isolates were susceptible to
most antibiotics, resistance to penicillin, co-trimoxazole and
ciprofloxacin was observed for, respectively, 72.7%, 41.4%, and
26.7% of the isolates. Notably, the spa-CC064 and t091 isolates
collected after 2000 showed increased resistance to co-trimoxazole
and ciprofloxacin compared to spa-CCs/spa-types isolated before
2000. This increased resistance seems to coincide with the
increased treatment of patients with co-trimoxazole (Figure 4).
Accordingly, co-trimoxazole-resistant isolates were only obtained
from patients treated with this antibiotic, and co-trimoxazole-
resistance was not observed for HC isolates (Table 3).
Discussion
Although S. aureus carriage has been linked to relapses in GPA for
many years, it had yet to be determined to which extent different S.
aureus antigens or types could contribute to GPA. The present
study was therefore undertaken to investigate the humoral immune
responses of GPA patients against S. aureus antigens in relation to
Figure 4 | Co-trimoxazole treatment and resistance over time.The percentage of patients treated with co-trimoxazole at the time of S. aureus isolation in
each specific period is shown in black bars. The percentage of co-trimoxazole resistant S. aureus isolates, determined with VITEK2 or disk diffusion,
is shown in white bars. Some adjacent years of S. aureus collection were taken together when the single years contained only few S. aureus isolates. On top
of the bars, the numbers of S. aureus isolates within that period are shown.Over time, an almost parallel increase was observed in the percentage of patients
treatedwith co-trimoxazole at the time of S. aureus isolation and the percentage of co-trimoxazole resistant S. aureus isolates (MannWhitneyU test: p5 9
3 1029 and p 5 3 3 10212 respectively).
Table 2 | Clinical data of GPA patients whose S. aureus isolates were typed
GPA patients (n 5 71)
No. of males (%) 40 (56.3%)
Age at inclusion, years, mean 6 SD 54.7 6 15.2
Disease duration at inclusion, years, median (range) 4.1 (0–19.9)a
No. with limited/generalized disease 27/44
Follow-up time, years, median (range) 11.6 (0.2–22.2)
No. of patients with relapse(s) after first isolate (%) 40 (56.3%)
No. of relapses in relapsing patients, median (range) 3 (1–13)
S. aureus isolates (n 5 210)
Collection period 1990–2012
No. of obtained S. aureus isolates per patient: 1 13 patients
2 18 patients
3 15 patients
4 14 patients
5 8 patients
6 2 patients
8 1 patient
No. of isolates obtained during co-trimoxazole/other antibiotic treatment (%) 115 (54.8%)/9 (4.3%)
No. of isolates obtained during vasculitis treatmentb (%) 117 (55.7%)
No. of isolates obtained during quiescent/active disease (%) 191 (91.0%)/19 (9.0%)
BVAS in active patients, median (range) 4 (2–14)
aTwo patients were included at the time of diagnosis of the disease.
bAt the time of S. aureus sampling, 15 patients were treated with azathioprine only, 22 with prednisolone only, one with methotrexate only, 4 with cyclophosphamide only, 32 with azathioprine in
combination with prednisolone, one with methotrexate in combination with prednisolone, 43 with cyclophosphamide in combination with prednisolone, and 9 patients with mycophenolate mofetil in
combination with prednisolone. Abbreviations: BVAS 5 Birmingham Vasculitis Activity Score.
www.nature.com/scientificreports
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the genetic diversity of their S. aureus isolates. For this purpose, we
studied S. aureus antigen-specific serum IgG levels in a large cohort
of GPA patients, who were monitored for over 20 years at our hos-
pital, in combination with extensive genotyping of their S. aureus
isolates.
Bead-based Luminex flow cytometry of 59 S. aureus antigens
revealed that GPA patients had circulating antibodies against many
staphylococcal antigens and that antibody levels in individual patients
were constant over time, irrespective of their disease state. Patients
carrying S. aureus had overall higher anti-staphylococcal IgG levels
than patients not carrying S. aureus, confirming previous observa-
tions25. The exact role of anti-staphylococcal antibodies is still
debated. On the one hand, they could reflect the properties of the
colonizing S. aureus type and/or infection episodes while, on the
other hand, they could protect against colonization and/or infection.
Persistent carriers of S. aureus have an increased risk of developing
staphylococcal infections, which are in 80% of the cases caused by the
endogenous strain16,26. In spite of this, persistent carriers have a lower
risk of death by bacteremia compared to non-carriers27. This reduced
risk could be the consequence of increased levels of protective anti-
bodies against S. aureus that may accumulate due to long-term expo-
sure to the colonizing strain(s)25,28. Unexpectedly, all GPA patients,
irrespective of treatment with corticosteroids and/or immunosup-
pressives, had overall lower levels of anti-staphylococcal IgG than
HC, while their total IgG levels were comparable. Moreover, we have
previously shown that antibody responses following influenza vac-
cination in GPA patients and HC are similar, suggesting that the S.
aureus-specific IgG response of GPA patients is aberrant29. The exact
causes for the lower anti-staphylococcal IgG levels in GPA patients
are yet unknown. Most likely, this relates to the S. aureus-specific
immune response in GPA patients, since all patient isolates contained
the genes for important host colonization factors, like ClfA, ClfB and
FnbpA, against which their hosts showed lower IgG levels than HCs.
To explore the diversity of S. aureus carried by GPA patients, a
large number of isolates sampled between 1990 and 2012 was char-
acterized by spa-typing and MLVF. This revealed 55 different spa-
types, with 5 predominant spa-types covering more than 50% of the
isolates. The subsequent MLVF analysis revealed a considerable
diversity with 95 different banding patterns. A comparison of the
spa-types from the present collection with the Ridom Spa Server
(October 2014) comprising 13881 different spa-types submitted by
107 countries with isolation dates from 2003 onwards, revealed that
four of the predominant spa-types of our patient isolates are amongst
the 20 most common spa-types. Additionally, a recent study on the
diversity of 206 methicillin-resistant S. aureus isolates collected at
our hospital between 2006 and 2012 revealed a similar diversity (107
MLVF banding patterns, 66 spa-types) as observed for our GPA
isolates30. Taken together, these observations imply that the present
GPA S. aureus collection mirrors the general S. aureus population
structure after 2003.
While the Ridom Spa Server includes S. aureus typing results for
different patient populations, other studies focused on particular
diseases associated with increased S. aureus carriage rates, such as
epidermolysis bullosa (EB) and cystic fibrosis (CF). A recent study
from our hospital revealed that S. aureus isolates from EB patients
were highly diverse and that these patients carried different types that
fluctuated over time31,32. Surprisingly, the spa-types identified in the
EB patient population did not overlap with the spa-types from the
present GPA collection. A German multicenter study investigating
the genetic diversity of S. aureus isolates from 195 CF patients iden-
tified 269 different spa-types among ,4000 isolates collected
between 2008 and 2011 (ECCMID 2014 Abstract No. eP166). Two
of the four most prevalent spa-types, t084 and t091, overlapped with
the dominant spa-types in the present collection, underscoring the
dominancy of these spa-types during the past decade.
In the present study, we have for the first time correlated spa-CCs/
types with antibiotic resistance profiles. Although the overall anti-
biotic resistance of the patient isolates was very low, the abundance of
co-trimoxazole-resistant isolates was higher amongst the more
recent isolates, coinciding with an increase in co-trimoxazole treat-
ment. This suggests that prolonged co-trimoxazole treatment either
induced or selected for co-trimoxazole resistance. Interestingly,
Table 3 | Antibiotic resistance profiles of the S. aureus isolates from GPA patients and HC in relation to the dominant spa-CCs/types
spa-CC/type All spa-CC084 spa-CC012 spa-CC062 spa-CC064 t091 Others HC
No. of isolates (%) 210a (100) 37 (17.6) 28 (13.3) 13 (6.2) 53 (25.2) 19 (9.0) 60 (28.6) 18 (100)
Year of isolation, mean 6 SD ND 1995 6 3 1996 6 5 2003 6 7 2005 6 5 2007 6 4 1999 6 7 2008 6 1.6
Chloramphenicol 1.5 0 0 0 6C 0 0 0
Ciprofloxacin 26.7 4 0 0 94 11 0 0
Clindamycin (const.) 6.1 0 4 0 9E 11E 7E 10
Co-trimoxazole 41.4 30 11D 23d 94 84D 7d 0
Erythromycin 10.1 0 4 42M & MP 13E 16E OR M 7E 16
Fosfomycin 0.5 0 4 0 0 0 0 0
Fusidic acid 0.5 0 0 4 4f 0 2F 0
Gentamicin 0 0 0 0 0 0 0 0
Kanamycin 0 0 0 0 0 0 0 0
Linezolid 0.5 0 0 0 2C 0 0 0
Mupirocin 14.2 0 11MR 0 21mr 74MR 0 0
Oxacillin 0 0 0 0 0 0 0 0
Penicillin 72.7 85BL 86BL 42BL 96BL 21BL 63BL 72
Rifampicin 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0
Tetracycline 8.6 15t 4 42T 13 40 6T 10
Tobramycin 3.1 0 0 0 0 0 3.4A 0
Vancomycin 0 0 0 0 0 0 0 0
aFor 197 S. aureus isolates the antibiotic resistance profile to 18 different antibiotics was determined using the VITEK2 system, and for one isolate using the standard disk diffusion assay. Twelve S. aureus
isolates grew neither in the VITEK2 system nor in the standard disk diffusion assay; these isolates were thymidine-dependent, resulting in co-trimoxazole resistance. Numbers are percentages. The presence of
antibiotic resistance genes in all 210 S. aureus isolates was determined by the DNA microarray system (Alere Technologies GmbH, Jena, Germany) and is indicated with letters. Abbreviations of the
resistance genes: BL 5 b-lactamase, A 5 aadD, D 5 dfrA, E 5 ermC (& ermB), M 5 mrsA, MP 5 mpbBM, C 5 cat, T 5 tetK, F 5 Q6GD50, MR 5 mupR. Capital letters indicate that in nearly all isolates (.95%) the
observed resistance phenotype is explained by the presence of the resistance gene. Small letters indicate that only in a fraction (,50%) of the isolates the resistance phenotype is explained by the resistance
gene. ND 5 not determined.
www.nature.com/scientificreports
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ciprofloxacin resistance was almost solely associated with spa-CC064
andmupirocin resistance with spa-type t091, two spa-CCs/types that
were predominant in the later years of isolation. These associations
between years of isolation, spa-types, antibiotics resistance and anti-
biotic therapy are highly relevant not only in relation to GPA patient
treatment and the prevention of emerging antibiotic resistance, but
also for other S. aureus infections. In addition, the abundance of
identified co-trimoxazole-resistant S. aureus isolates warrants fur-
ther investigations on the efficacy of prolonged co-trimoxazole treat-
ment in GPA patients.
Superantigens, like TSST-1, cause non-specific activation of T cells
resulting in polyclonal T cell proliferation and massive cytokine
release33. Previous studies have shown that GPA patients carrying
tst-1-positive S. aureus isolates have an increased risk for disease
relapses15. Although the present study revealed only 23/210
(10.1%) tst-1-positive S. aureus isolates, all GPA patients, both car-
riers and non-carriers, had high IgG levels against TSST-1. This
suggests that all patients encountered tst-1-positive S. aureus strains
during their life. Potential associations between S. aureus and other
autoimmune diseases, namely rheumatoid arthritis (RA) and mul-
tiple sclerosis (MS), have previously been investigated. RA patients
were shown to carry different S. aureus types compared to HC and
had higher IgG levels against TSST-134. More recently, relapsing MS
patients were shown to carry S. aureus isolates positive for the SAg
gene sea more frequently than non-relapsing MS patients35.
However, in the present study no apparent associations between
clinical data of GPA patients and particular S. aureus types were
found.
In conclusion, the present study investigated for the first time a
large cohort of GPA patients and their S. aureus isolates over an
extended time period. On the host side, we show that GPA patients
have overall lower anti-staphylococcal IgG responses than HC. On
the pathogen side, we show that GPA patients carry S. aureus types
that are widely represented amongst the general S. aureus popu-
lation. We therefore conclude that GPA is not associated with a
particular S. aureus genotype, but rather with a lower ability of
GPA patients to mount potentially protective antibody responses
to S. aureus, despite their long-term exposure to this pathogen.
Notably, the fact that we do not find a particular S. aureus type
associated with GPA does not exclude a role for S. aureus carriage
or the expression levels of particular S. aureus virulence factors in the
GPA disease pathogenesis.We consider our findings important since
they may lead to a full definition of the role of S. aureus in GPA.
Accordingly, we believe that this lead will be relevant to the research
community that investigates the role of bacterial pathogens in the
onset and relapse of autoimmune diseases, and the clinicians who
treat patients with such pathogen-related autoimmune diseases in
general and GPA in particular.
Methods
GPApatients andHC.This retrospective study included 85GPApatients (71 nasal S.
aureus carriers and 14 non-carriers) and 18HC (10 nasal S. aureus carriers and 8 non-
carriers). All patients were PR3-ANCA positive, fulfilled the Chapel Hill Consensus
Conference definitions for the diagnosis of GPA and regularly visited the University
Medical Center Groningen (UMCG, The Netherlands)36. The patients were selected
based on availability of stored S. aureus isolates and/or serum samples, but formed a
representative cohort of all GPA patients from our hospital. From 21 S. aureus-
carrying GPA patients and all 14 non-carriers serum samples from two to three
different time points (diagnosis, remission, relapse) were included in the multiplex S.
aureus antibody assay, as well as previously collected and described sera from the 18
HC25,37. From each HC at least two sera from different time points were included.
Clinical data of the patients andHC, whose sera were used, are summarized in Table 1
and detailed in Supplementary Table 1. Clinical characteristics and information on
the respective S. aureus isolates included in DNA typing from all S. aureus-carrying
patients and HC are summarized in Table 2 and detailed in Supplementary Tables 2
and 3. This study was approved by the Medical Ethics Committee of the UMCG and
conducted in accordance with the guidelines of the Declaration of Helsinki. Written
informed consent was obtained from all patients.
Multiplex S. aureus antibody assay.The relative amounts of serum IgGs against 59 S.
aureus antigens were determined by bead-based Luminex flow cytometry (xMAPH,
Luminex Corporation, Austin, Texas, USA) as previously described (Supplementary
Table 4)25,38.
Bacterial isolates. From 71 GPA patients, a total of 210 S. aureus nasal isolates (1–8
per patient, median 3) with isolation dates between 1990 and 2012 were included
(Supplementary Table 3). Seventy-five of these isolates belonged to 21 patients whose
anti-staphylococcal serum IgG levels were assayed. In addition, 18 S. aureus isolates
(1–3 per HC, median 2) from the previously described HC with isolation dates
between 2007 and 2012 were included as controls (Supplementary Table 3)25,37.
S. aureus DNA typing. spa-typing and MLVF were performed as previously
described23,39. To determine the clonal relatedness of the S. aureus population, the
based upon repeat patterns (BURP) algorithm was applied (Ridom StaphType
software 2.2.1)24.
Antibiotic susceptibility testing. Antibiotic susceptibility was determined using the
VITEK 2 system (bioMe´rieux, Marcy l’Etoile, France) with AST P633 cards,
according to the manufacturer’s protocol. The VITEK 2 minimum inhibitory
concentration (MIC) results were interpreted using the VITEK 2 Advanced Expert
System following EUCAST guidelines (www.eucast.org).
DNA microarray-based genotyping. The presence of genes for staphylococcal
virulence factors or antibiotic resistance in S. aureus isolates from patients and HC
was determined with the Clondiag S. aureus Genotyping Kit 2.0 following the
manufacturer’s instructions (Alere Technologies GmbH, Jena, Germany)40,41.
Statistical analyses. Statistical analyses were performed with GraphPad Prism
(Version 6, La Jolla, California) or SPSS 20 (Chicago, USA). Differences between
groups were tested for statistical significance using one-way ANOVA in case of a
parametric variable andMann-Whitney-U or theKruskal-Wallis test in case of a non-
parametric variable. A two-sided p value , 0.05 was considered to be statistically
significant. Parametric variables are given as means 6 SD. Non-parametric variables
are given as median with range.
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